Health · 4 views
Brepocitinib yields improvements in cutaneous sarcoidosis
For patients with cutaneous sarcoidosis (CS), brepocitinib is associated with dose-dependent and clinically meaningful improvements, according to a study published online in JAMA Dermatology to coincide with the annual meeting of the…
Summary
For patients with cutaneous sarcoidosis (CS), brepocitinib is associated with dose-dependent and clinically meaningful improvements, according to a study published online in JAMA Dermatology to coincide with the annual meeting of the American College of Rheumatology, held from Nov. 6 to 11 in Orlando, Florida. Misha Rosenbach, M.D., from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues examined the efficacy and safety of brepocitinib in adults with CS in the Phase II portion of a multicenter, randomized, placebo-controlled trial.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trialContinue reading
- STAT+: Influential preventive services panel to meet for first time in more than a yearContinue reading
- Quadruple Agonist Reduced Weight Without Major Muscle Loss in Mid-Stage TrialContinue reading
- Brain model offers new explanation for memory formation and how dementia disrupts itContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow